Related Experiment Video
Updated: May 3, 2026

Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury
Published on: January 20, 2023
Current neuropharmacologic interventions for the management of brain injury agitation
1Department of Physical Medicine and Rehabilitation, Rehabilitation and Research Center, Medical College of Virginia, Box 980661, Richmond, VA 23098-0661, USA.
Abstract:
Agitation following brain injury is a significant and difficult problem; severe agitiation is most effectively treated by concurrent environmental, behavioral, and pharmacologic interventions. Delirium and agitation are briefly compared, however, a more thorough discussion of this topic appears in other articles within this issue. This article reviews the current literature in regard to practical pharmacologic interventions for agitation following brain injury and outlines short-term and long-term strategies. Common and serious side effects, as well as unique characteristics for each medication are highlighted.
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer's Disease: Treatment
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Drug Therapy
Antianxiety Medications
Cardiopulmonary Resuscitation IV: Pharmacological Management
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

